

1 A global database of COVID-19 vaccinations

2

3 Edouard Mathieu¹, Hannah Ritchie^{1,2*}, Esteban Ortiz-Ospina^{1,2}, Max Roser^{1,2}, Joe Hasell^{1,2,3},
4 Cameron Appel¹, Charlie Giattino^{1,2}

5

6 ¹ Our World in Data

7 ² Oxford Martin Programme on Global Development, University of Oxford, Oxford, United
8 Kingdom

9 ³ Department of Social Policy and Intervention, University of Oxford, Oxford, United Kingdom

10

11 * Corresponding author

12

13 Abstract

14 An effective rollout of vaccinations against COVID-19 offers the most promising prospect of
15 bringing the pandemic to an end. We present the *Our World in Data* COVID-19 vaccination
16 dataset, a global public dataset that tracks the scale and rate of the vaccine rollout across
17 the world. This dataset is updated regularly, and includes data on the total number of
18 vaccinations administered; first and second doses administered; daily vaccination rates; and
19 population-adjusted coverage for all countries for which data is available (138 countries as of
20 17 March 2021). It will be maintained as the global vaccination campaign continues to
21 progress. This resource aids policymakers and researchers in understanding the rate of
22 current and potential vaccine rollout; the interactions with non-vaccination policy responses;
23 the potential impact of vaccinations on pandemic outcomes such as transmission, morbidity,
24 and mortality; and global inequalities in vaccine access.

25

26 Main

27 As of 17 March 2021 there have been 2.7 million confirmed deaths and 121 million
28 confirmed cases of SARS-CoV-2 — the virus that causes COVID-19.¹ Since the beginning of
29 the pandemic and up until today, virus transmission and mortality has been reduced through
30 a range of measures: precautionary actions from individuals including social distancing,
31 wearing facemasks, hand hygiene, and restricting interpersonal contact to outdoor settings;
32 widespread testing to identify individuals infected with the virus; and non-pharmaceutical
33 policy responses from governments – including school and workplace closures; bans on
34 public gatherings; travel restrictions; and stay-at-home orders.^{2,3} Now, with the successful
35 development, evaluation and production of multiple vaccines, governments are turning
36 towards vaccination as an essential solution to the pandemic.

37

38 To understand the scale and rate of the vaccine rollout, we need timely, comparable data
39 across countries. The *Our World in Data* COVID-19 vaccination dataset provides a public
40 aggregated global dataset on administered vaccinations. It covers the full period from 13
41 December 2020 – the date of the first publication of vaccination data – and is being updated
42 regularly ever since. The COVID-19 vaccination dataset is continuously expanding as more
43 countries begin releasing official data on their new national vaccination campaigns. As of 17
44 March 2021, the dataset covers 138 countries. Our intention is to maintain this database for
45 the foreseeable future and include additional countries as the vaccination campaign starts in
46 a growing number of countries.

47

48 This dataset tracks the total number of COVID-19 vaccinations administered by country;
49 broken down by first and second doses (where national data is made available); and derived
50 daily vaccination rates and population-adjusted figures. The combination of these metrics
51 allows users to understand the scale and rate of vaccine rollouts relative to population;
52 compare rollout rates between countries; and assess differences in prioritization for
53 countries with one- and two-dose schedules. This data is compiled from official sources,
54 including health ministries, government reports and official social media accounts.

55

56 Our COVID-19 vaccination dataset is already used widely by journalists, policymakers,
57 researchers and the public. The World Health Organization (WHO) relies on this dataset for
58 its official COVID-19 dashboard.⁴ Our dataset is also used by policymakers to benchmark
59 the performance of national vaccination programs across countries. The WHO have also
60 relied on this dataset to understand the inequities in global vaccine access, using this

61 evidence to support calls for greater financial support for COVAX, a global initiative
62 supported by the WHO that is aimed at equitable access to COVID-19 vaccines

63

64 Our dataset has been used by all leading media outlets, including the New York Times, the
65 BBC, the Financial Times and The Economist.⁵⁻⁸ Global media plays an important role in
66 informing the public during this global pandemic, and it is essential that leading media
67 outlets have timely, transparent and reliable data to present to their audiences. The
68 demonstration of rapid vaccine rollouts across the world, and its potential impacts on
69 transmission and mortality has the potential to shape public attitudes towards vaccinations,
70 reduce vaccine hesitancy, and ultimately lead to an improved response to the pandemic. An
71 effective vaccination response relies on high uptake rates.⁹ As such, our dataset plays a key
72 role in building the public trust that is essential to an effective global response to the COVID-
73 19 pandemic.

74

75 Our dataset has been widely-used by the scientific community across multiple disciplines. It
76 has been used to highlight global inequalities in vaccine access, with strong calls to action
77 for the acceleration of financial and policy response efforts to close the existing gaps.¹⁰ It
78 has been used by researchers to identify countries with particularly effective vaccine rollouts,
79 thereby enabling an analysis of how this was achieved.¹¹ These analyses emphasize a
80 range of drivers that explain the large differences across countries that we document:
81 differences in the funding of the development and production of the vaccines; differences in
82 the scheduling and management of vaccinations; differences in public trust and uptake
83 rates; and differentiated responsibilities between national, regional and local level actors.¹²
84 Health policy researchers have used this dataset to assess differences in vaccine
85 prioritization strategies — for example, which groups should be offered the vaccine first.¹³
86 Other research groups have combined it with vaccine development data to provide a
87 complete overview of the global vaccine landscape.¹⁴ It has been used by researchers
88 looking at the role of vaccine hesitancy, and how to design public messaging based on these
89 concerns.¹⁵

90

91 As vaccination campaigns continue to scale, evidence for their effectiveness in reducing
92 transmission, severe disease and death will become increasingly important. Our dataset
93 provides an essential input for epidemiologists who study these questions. Integrating it with
94 other epidemiological data can help researchers evaluate these outcomes.^{16,17} Evidence of
95 positive impacts of vaccination on transmission and mortality can also in turn help to
96 strengthen public trust.

97 The rest of this article is organized as follows: The Results section presents the key metrics
98 used to track vaccine rollout in this dataset, and the headline results so far. The Discussion
99 section outlines the significance and limitations of this work. The Methods section provides
100 detailed descriptions of the underlying methods and sources used to build this global
101 dataset.

102 Results

103 Global coverage of COVID-19 vaccination campaigns

104 The first published reports of COVID-19 vaccinations (outside clinical trials) occurred on 13
105 December 2020 in the United Kingdom. Our live dataset presents the time-series of
106 vaccinations across the world since then.


107

108 To date, 138 countries reported vaccinations, and are included in this dataset. As of 17
109 March 2021, there have been 400 million doses administered globally. 3% of the world
110 population have received at least one dose of an approved vaccine. This highlights
111 important inequalities in global vaccine access (Figure 1). At the time of writing most high-
112 and middle-income countries have begun vaccination rollouts, but many low-income
113 countries have not (Figure 2). Only 11 countries in Sub-Saharan Africa had started
114 community vaccination.

115

COVID-19 vaccine doses administered, Mar 17, 2021

Total number of vaccination doses administered. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).




Source: Official data collated by Our World in Data

CC BY

116
117
118

Figure 1: Cumulative number of COVID-19 doses administered by country. This represents the current coverage of the global vaccination rollout.

119



120
121
122
123
124

Figure 2: Cumulative number of COVID-19 doses administered per 100 people, measured against gross domestic product (GDP) per capita. GDP per capita is PPP-adjusted, and measured in international-dollars.

125 Large differences in vaccination rates between countries

126 The data reveals large differences in the scale of the vaccine rollout across countries. As of
127 17 March 2021, we see the cumulative number of doses administered per 100 people range
128 from 110 per 100 in the case of Israel, to 0.01 doses per 100 in countries that have just
129 begun their vaccination campaigns, such as Nigeria, Iran and Vietnam (**Figure 3**).¹

130


131 These differences in vaccination coverage are dependent on several factors. First, the date
132 when countries started national vaccination campaigns: the United Kingdom, for example,
133 began community vaccination on 8 December 2020 while other countries have not yet
134 begun their vaccine rollouts.

135

¹ As discussed below, the number of doses can exceed the number of people due to multiple dose vaccination programs.

COVID-19 vaccine doses administered per 100 people, Mar 17, 2021

Total number of vaccination doses administered per 100 people in the total population. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).



Source: Official data collated by Our World in Data


CC BY

136
137
138
139
140

Figure 3: Cumulative vaccine doses administered per 100 people in the total population.
Shown is the global situation as of 17 March 2021.

141 Second, the rate of vaccinations over time. We see large differences in these rates between
142 countries (**Figure 4a, b**). Israel has received significant attention for the rate of its
143 campaign.¹¹ As well as being one of the first countries to begin vaccinations, it also
144 maintained a consistently high rate of vaccinations over time. This is reflected in its steep
145 linear time-series trend of cumulative doses (**Figure 4a**) and consistently high rate of daily
146 doses (**Figure 4b**). Since the end of December 2020 Israel has averaged a rate of
147 approximately one dose per 100 people per day — more than twice the rate of most
148 countries. Rosen et al. (2021) looked at the contributors to Israel's success and identified
149 factors such as the organisational and logistical capacity of its community-based healthcare
150 providers; a clear prioritisation framework; and effective outreach efforts to the public as
151 important.¹¹ Lee al. (2021) also looked at the factors in Israel's success, and emphasized the
152 high level of public trust in particular.¹²
153

154 Most countries which have achieved the fastest vaccine rollouts to date — Israel, United
155 Arab Emirates, United Kingdom, United States, Bahrain, and Chile — are high-income
156 countries. We see from Figure 2 that income matters. But the significant variation at different
157 income levels shows that it's not the only factor. This can be the basis for research into
158 effective strategies at different income levels.



159

160 **Figure 4: Vaccine doses administered per 100 people: (a)** shown as the cumulative total per 100
161 people; and **(b)** daily doses administered per 100 people (7-day smoothed) for select countries.

162
163

164 Different approaches and prioritization strategies between countries


165 The *Our World in Data* COVID-19 vaccination dataset allows for comparison of cumulative
166 doses administered, and for a subset of countries, disaggregated data on the number of first
167 and second doses is available. This allows for a comparison of prioritization strategies – a
168 central policy and research question.

169

170 Our data highlights large differences in approaches taken by different countries. Some
171 countries — the United Kingdom being the most prominent example — have taken a ‘first
172 dose first’ approach, delaying the delivery of a second vaccine dose to achieve wider single-
173 dose coverage within the total population. This is reflected in the data which shows the
174 share of the total people that have received at least one dose of a COVID-19 vaccine
175 **(Figure 5a)** and the share that have been fully vaccinated **(Figure 5b)**. As of 17 March
176 2021, 37.2% of the total population had received at least one dose, but only 2.6% had
177 received both doses. Other countries have put greater emphasis on giving two doses to a
178 smaller share of the population. In these countries a large share of those who received the
179 first dose have already received the second dose: In Israel, 59.5% had received at least one
180 dose, and 50.9% had been fully vaccinated. In the United States, 22% had received one
181 dose and 12% had been fully vaccinated.

182

183 Differences in prioritization have received particular attention in Europe. The ‘first dose first’
184 approach favoured by the United Kingdom has been frequently contrasted with the approach
185 of many countries in the European Union.^{18–20} This is reflected in our dataset: Germany, for
186 example, has administered a first dose to a much smaller share of the population (8.1%) but
187 has fully vaccinated a higher share than the UK (3.6%). While the share of the population
188 that received a first dose in Germany was much lower than in the UK, the share who
189 received a second dose is actually higher.



190


191 **Figure 5: Share of the total population that have: (a) received at least one dose of the COVID-19**
192 **vaccine; and (b) been fully vaccinated against COVID-19, for select countries.**

193

194 Discussion

195 The rapid development, testing and manufacturing of multiple effective vaccines against
196 SARS-CoV-2 was a ground-breaking achievement in 2020. Never before in history has a
197 vaccination campaign started so very soon after a new pathogen was identified. In many
198 cases it took many years or decades until a vaccine was developed (Figure 6). In the case of
199 COVID-19 scientists have developed several, highly efficacious vaccines within the same
200 year. The question now is whether the global rollout of the vaccine can match the speed with
201 which the vaccine was developed: whether they can be administered quickly and equitably
202 across the world.

203



204
205
206
207
208
209
210

Figure 6: Timeline of innovation in the development of vaccines. Each bar begins in the year in which the pathogenic agent was first linked to the disease and the bar ends in the year in which a vaccination against that pathogen was licensed in the US.

211
212
213
214
215
216
217
218

To do this, governments and public health officials need to understand the most effective approaches to mass vaccination rollouts and prioritize the administration in a way that minimizes morbidity and mortality from the disease. The dataset that we present here provides an essential resource to support this. It allows analysts to track vaccinations over time in a specific country, and also to compare vaccination rates and prioritization strategies across countries. Combined with epidemiological data, it is a vital input for researchers to understand how vaccination affects the transmission and health outcomes of COVID-19.

219
220
221
222
223
224
225

Communicating such research on the efficacy of vaccines is in turn essential for building public trust and reducing vaccine hesitancy.^{21,22} Kreps et al. (2021) found that perceived vaccine efficacy was the strongest predictor of COVID-19 vaccine uptake in the United States.²³ Sherman et al. (2021) studied people's willingness to be vaccinated against COVID-19 and their attitude towards vaccines.²⁴ The researchers documented that the effectiveness of vaccines in reducing disease is a particularly important argument.

226
227

It is important to highlight what we do not try to achieve with this dataset collection. We only collect data on doses administered — we do not include data on the number of doses

228 manufactured, ordered or delivered. In the collection of data on administered doses we also
229 do not audit official reports beyond technical validation (see Methods section). And we also
230 do not attempt to assess vaccine effectiveness or the impacts of vaccinations on pandemic
231 outcomes. This is beyond the scope of this resource.

232

233 If we want to understand anything about vaccines – effectiveness, policy responses,
234 perceptions – then we need to know how many vaccines have been administered. Our
235 dataset fills this gap.

236 Methods

237 In this section we first provide a description of the metrics made available in this dataset,
238 followed by information on how this data was collected. Finally, we describe how it is
239 published as a complete, open-access dataset and how it can be explored via our online
240 web application.

241

242 Metrics included in this dataset

243 The metrics included in this dataset are a combination of original metrics reported by official
244 sources, and derived metrics calculated by *Our World in Data*.

245

246 The nine metrics included in this dataset are the following.

247

- 248 1. **Total doses administered.** This is a count of all doses given. Since several
249 vaccines require multiple doses this count may be higher than the total number of
250 people vaccinated.
- 251 2. **Total doses administered per 100 people.** This is ‘Total doses administered’ per
252 100 people of the total population.
- 253 3. **Daily vaccinations.** If official sources provide daily updates of vaccinations
254 administered, this is included.
- 255 4. **Rolling average of daily vaccinations over 7 days.** For countries that don't report
256 data on a daily basis, we assume that the number of administered doses was the
257 same on all days over any periods in which no daily data was reported. This
258 produces a complete series of daily figures, which is then averaged over a rolling 7-
259 day window.
- 260 5. **Daily doses administered per million people.** This is the rolling average of daily
261 vaccinations over 7 days, per million people within the total population.

- 262 6. **Number of people that have received at least one vaccine dose.** Depending on
263 the vaccine schedule (a one or two-dose vaccine), this may or may not match the
264 number of people fully vaccinated. If a person receives the first dose of a 2-dose
265 vaccine, this metric goes up by one. If they receive the second dose, the metric stays
266 the same.
- 267 7. **Share of the total population that have received at least one vaccine dose.** This
268 is the number of people that have received at least one vaccine dose per 100 people
269 in the total population.
- 270 8. **Number of people that are fully vaccinated.** This is the total number of people who
271 received all doses prescribed by the vaccination protocol. If a person receives the
272 first dose of a two-dose vaccine, this metric stays the same. If they receive the
273 second dose, the metric goes up by one.
- 274 9. **Share of the total population that are fully vaccinated.** This is the number of
275 people that have received all doses prescribed by the vaccination protocol per 100
276 people in the total population.

277

278 Not all metrics are available for all countries. The availability is dependent on the granularity
279 of reporting provided by the official sources. For example, not all countries provide a
280 breakdown of doses administered by first or second doses. In this case, only the total
281 number of administered doses can be provided for this country.

282

283 **Data collection methods**

284 Raw data on vaccination doses administered is collected through a combination of manual
285 and automated means. This collection process differs by country, but can be broadly defined
286 by three methods.

287

288 Firstly, for a number of countries, figures reported in official sources — including government
289 websites, health ministries, dedicated dashboards, and social media accounts of national
290 authorities — are recorded manually as they are released.

291

292 Secondly, where official sources release vaccination figures in a consistent, machine-
293 readable format, or where structured data is published at a stable location, we have
294 automated the data collection via Python scripts that we execute every day. These
295 automated scripts are made available in our GitHub repository

296 ([https://github.com/owid/covid-19-](https://github.com/owid/covid-19-data/blob/master/scripts/scripts/vaccinations/automations/)
297 [data/blob/master/scripts/scripts/vaccinations/automations/](https://github.com/owid/covid-19-data/blob/master/scripts/scripts/vaccinations/automations/)). These are regularly audited for

298 technical bugs to ensure data validity (see ‘Technical Validation’, below).

299

300 Third, in some instances – where national data is not made available in machine-readable
301 format by official sources, but is aggregated by third-party sources – we source data from
302 non-official publishers (e.g. <https://covid19tracker.ca/vaccinationtracker.html> for Canada).

303 These are also regularly audited for accuracy against the original official sources.

304

305 **Calculating derived metrics**

306 Derived metrics are calculated from the raw official counts in two ways.

307

308 1. Population-adjusted metrics. This normalizes total doses, first doses, and second doses
309 to their counts per 100 people within the total population. This allows users to compare the
310 pace and scope of the vaccination rollout across countries. Vaccinations administered per
311 100 people are calculated by dividing administered doses by total population figures,
312 sourced from the latest revision of the United Nations World Population Prospects.²⁵ The
313 exact population values used in these calculations are also provided in our GitHub repository
314 (https://github.com/owid/covid-19-data/blob/master/scripts/input/un/population_2020.csv).

315

316 2. Daily rolling averages. Not all countries report figures at a daily frequency. In order to
317 facilitate cross-country comparisons over time, we therefore derive a ‘smoothed’ daily
318 vaccination series calculated as the seven-day moving average. It is calculated as the right-
319 aligned rolling seven-day average of a complete series of daily changes. For countries for
320 which no complete series of daily changes is available from our source, we derive it by
321 linearly interpolating the cumulative totals. The exact code used to derive the 7-day moving
322 average is available online (see ‘Code Availability’, below).

323

324 **Criteria for inclusion and coverage**

325 To be included in this dataset, countries must provide at least one data point on the number
326 of vaccine doses administered via a trusted country-specific source such as a health
327 ministry, government report or official national account. Reports on the number of vaccine
328 doses ordered or distributed are not included; this dataset only includes doses administered.
329 Vaccinations administered in clinical trials are also not included.

330

331 As of 17 March 2021, the vaccination dataset covers 138 countries. This coverage will
332 continue to expand as more countries begin vaccination campaigns.

333

334 **Technical validation**

335 The *Our World in Data* COVID-19 vaccination database represents a collation of publicly
336 available data published by official sources. The main quality concern for the database itself
337 is whether it represents an accurate record of the official data. We employ several strategies
338 to ensure that this is the case.

339

340 First, all automated collection of data, whether obtained from official channels or non-official
341 publishers, is subject to initial manual verification when it is added to our database for the
342 first time.

343

344 Second, we employ a range of data validation processes, both for our manual and
345 automated time series. We continually check for invalid figures such as negative or illogical
346 values, out-of-sequence dates, implausible changes in time-series data, invalid population-
347 adjusted values, and for each country we test for abrupt changes in vaccination rates.

348

349 Third, our vaccination data is viewed and used by millions of people every day — either
350 through direct usage or third-party usage (such as news reports, social media and other
351 sharing channels). This includes employees of health ministries, researchers, journalists,
352 and policymakers from across the world. We receive large amounts of feedback from this
353 user base. This provides a final ‘crowd-sourced’ verification method that has been shown to
354 be effective in highlighting any discrepancies to official data sources.

355

356 **Data access and publication**

357 Vaccination data is updated daily and is made available via two channels. Firstly, all data
358 and scripts used for data collection are published and updated in our public GitHub
359 repository (<https://github.com/owid/covid-19-data/tree/master/public/data/vaccinations>). This
360 provides a transparent resource for users to download the data in CSV and JSON formats;
361 replicate the data collection and metric derivation process; and monitor any changes or
362 additions to this process.

363

364 To allow journalists, researchers, policymakers and the public to understand the evolution of
365 the global COVID-19 vaccination rollout, we make all of this data explorable at our online
366 web publication (ourworldindata.org/covid-vaccinations). There we provide interactive
367 visualizations of all available vaccination metrics to allow users to track and compare the
368 vaccination campaigns around the world. These interactive visualizations are built with our

369 custom visualization tool – the *Our World in Data Grapher* – and are made available open-
370 access. They are updated daily in sync with updates in our GitHub repository.

371 Data availability

372 A live version of the vaccination dataset and documentation are available in a public GitHub
373 repository at <https://github.com/owid/covid-19-data/tree/master/public/data/vaccinations>.

374 This data can be downloaded in CSV and JSON formats.

375 Code availability

376 Our scripts for data collection, processing, and transformation, are available for inspection in
377 the public GitHub repository that hosts our data ([https://github.com/owid/covid-19-
378 data/tree/master/scripts/scripts/vaccinations](https://github.com/owid/covid-19-data/tree/master/scripts/scripts/vaccinations)).

379

380 References

- 381 1. Data as of 17 March 2021 from the online repository published by the Center for
382 Systems Science and Engineering (CSSE) at Johns Hopkins University: Dong, E., Du, H.,
383 & Gardner, L. (2020). An interactive web-based dashboard to track COVID-19 in real
384 time. .
- 385 2. Hale, T. *et al.* Tracker). *Nat. Hum. Behav.* (2021). doi:10.1038/s41562-021-01079-8
- 386 3. Hasell, J., Math, E., Beltek, D. & Macdonald, B. A cross-country database of COVID-19
387 testing. *Nat. Sci. Data* 1–7 (2020). doi:10.1038/s41597-020-00688-8
- 388 4. <https://covid19.who.int/info>.
- 389 5. <https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html>.
- 390 6. <https://www.bbc.co.uk/news/world-56237778>.
- 391 7. <https://ig.ft.com/coronavirus-vaccine-tracker/>.
- 392 8. <https://www.economist.com/graphic-detail/tracking-coronavirus-across-the-world>.
- 393 9. Kim, J. H., Marks, F. & Clemens, J. D. Looking beyond COVID-19 vaccine phase 3 trials.
394 *Nat. Med.* **27**, 205–211 (2021).
- 395 10. Wilson, B. S. & Tucci, D. L. Priorities for the COVID-19 pandemic at the start of 2021:
396 statement of the Lancet COVID-19 Commission. *Lancet* 947–950 (2021).

- 397 doi:10.1016/S0140-6736(21)00388-3
- 398 11. Rosen, B., Waitzberg, R. & Israeli, A. Israel's rapid rollout of vaccinations for COVID-
399 19. *Isr. J. Health Policy Res.* **6**, 1–14 (2021).
- 400 12. Lee, H., T. & Chen, H., A. Last-Mile Logistics of Covid Vaccination — The Role of Health
401 Care Organizations. *N. Engl. J. Med.* 685–687 (2021).
- 402 13. Cylus, J., Panteli, D. & Ginneken, E. Van. Who should be vaccinated first ? Comparing
403 vaccine prioritization strategies in Israel and European countries using the Covid-19
404 Health System Response Monitor. *Isr. J. Health Policy Res.* **1**, 4–6 (2021).
- 405 14. Shrotri, M., Swinnen, T., Kampmann, B. & Parker, E. P. K. An interactive website
406 tracking COVID-19 vaccine development. *Lancet Glob. Heal.* 19–21 (2021).
407 doi:10.1016/S2214-109X(21)00043-7
- 408 15. Alkandari, D., Herbert, J. A., Alkhalaf, M. A., Yates, C. & Panagiotou, S. SARS-CoV-2
409 vaccines: fast track versus efficacy. *The Lancet Microbe* **2**, e89–e90 (2021).
- 410 16. Dagan, N. *et al.* BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination
411 Setting. *N. Engl. J. Med.* 1–12 (2021). doi:10.1056/NEJMoa2101765
- 412 17. Ramos, A. M., Vela-Perez, M., Ferrandez, M. R., Kubik, A. B. & Ivorra, B. *Modeling the*
413 *impact of SARS-CoV-2 variants and vaccines on the spread of COVID-19.* (2021).
414 doi:10.13140/RG.2.2.32580.24967/2
- 415 18. Iacobucci, G. & Mahase, E. Covid-19 vaccination: What's the evidence for extending
416 the dosing interval? *BMJ* **372**, (2021).
- 417 19. Mahase, E. Covid-19 : Medical community split over vaccine interval policy as WHO
418 recommends six weeks. *BMJ* (2021). doi:10.1136/bmj.n18
- 419 20. Baraniuk, C. Covid-19 : How the UK vaccine rollout delivered success, so far. *BMJ*
420 (2021). doi:10.1136/bmj.n421
- 421 21. Vanderslott, S., Dadonaite, B. & Roser, M. Vaccination. *OurWorldinData.org* Available
422 at: <https://ourworldindata.org/vaccination>.
- 423 22. Verger, P. & Dubé, E. Expert Review of Vaccines Restoring confidence in vaccines in
424 the COVID-19 era. *Expert Rev. Vaccines* **19**, 991–994 (2020).
- 425 23. Kreps, S. *et al.* Factors Associated With US Adults' Likelihood of Accepting COVID-19
426 Vaccination. *JAMA Netw. Open* 1–13 (2020).
427 doi:10.1001/jamanetworkopen.2020.25594
- 428 24. Sherman, S. M. *et al.* COVID-19 vaccination intention in the UK : results from the

- 429 COVID-19 vaccination acceptability study (CoVAccS), a nationally representative
430 cross- sectional survey. *Hum. Vaccin. Immunother.* 1–10 (2020).
431 doi:10.1080/21645515.2020.1846397
- 432 25. United Nations, Department of Economic and Social Affairs, P. D. World Population
433 Prospects: The 2019 Revision, DVD Edition. (2019).
434
435